Treatment

medicine

Trigeminal Neuralgia Treatment Medicine Market Analysis, Overview, Growth, Demand and Forecast Research Report to 2026

The MarketWatch News Department was not involved in the creation of this content.

Nov 25, 2020 (The Expresswire) —
The report “Trigeminal Neuralgia Treatment Medicine Market” in Global to 2026 – Market Scope, Development, and Predictions offers the most up-to-date industry information on the actual market situation, and future outlook for vision frames and mountings in worldwide.

The research includes historic data from 2020 and forecasts until 2026 which makes the report a valuable resource for industry executives, presentation, sales and product managers, consultants, analysts, and other people looking for key industry data in a readily available document with clearly presented tables and Figures.

Request a sample copy of the report – https://www.absolutereports.com/enquiry/request-sample/16562110

Trigeminal Neuralgia Treatment Medicine market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Trigeminal Neuralgia Treatment Medicine business, the date to enter into the Trigeminal Neuralgia Treatment Medicine market, Trigeminal Neuralgia Treatment Medicine product introduction, recent developments, etc.

The Following Manufacturers Are Covered in This Report:

● Novartis Pharma AG ● Sihuan Pharma ● Wuhan Humanwell ● Raybow Pharma ● Jinan Jinda Pharmaceutical ● Sinopharm ● Jiangsu Tohope Pharma ● Yabang Medicine ● Taro ● Torrent Pharmas ● Wockhardt Bio AG ● Apotex Inc ● Teva Pharmas ● Zydus Pharms ● Unique Pharm ● Rubicon ● Sun Pharma Inds ● Glenmark Pharms Ltd ● Breckenride Pharm ● Amneal Pharms

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT – REQUEST SAMPLE

Trigeminal Neuralgia Treatment Medicine Market Breakdown Data by Type

● Carbamazepine ● Oxcarbazepine ● Others

Trigeminal Neuralgia Treatment Medicine Market Data by Application

● Hospitals ● Clinic ● Others

Inquire Or Share Your Questions If Any Before The Purchasing This Report – https://www.absolutereports.com/enquiry/pre-order-enquiry/16562110

Geographic Segmentation

The report offers exhaustive assessment of different region-wise and country-wise Breast Localization Needles markets such as U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. Key regions covered in the report are North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

For the period 2015-2026, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Breast Localization Needles market. For the period 2015-2020, it provides sales (consumption) analysis and forecast of different regional markets by Application as well as by Type in terms of volume.

Detailed TOC of Global Trigeminal Neuralgia Treatment Medicine Market Report, History and Forecast 2015-2026, Breakdown Data by Manufacturers, Key Regions, Types and Application

1 Trigeminal Neuralgia Treatment Medicine Market Overview

1.1 Product Overview and Scope of Trigeminal Neuralgia Treatment Medicine

1.2 Trigeminal Neuralgia Treatment Medicine Segment by Type

1.2.1 Global Trigeminal Neuralgia

Read More
dentist

Aesthetic Dental Center of Morris County Has The Best Dentist For All Dental Care and Treatment Procedures

Aesthetic Dental Center of Morris County Has The Best Dentist For All Dental Care and Treatment Procedures

Dover, NJ – Aesthetic Dental Center of Morris County has a reputation that precedes it. The dental clinic is known for its 5-star dental care and treatment services. Members of the Dover, New Jersey community who have in the past had negative dental care and treatment experiences have found that the dental team at Aesthetic Dental Center of Morris County pays attention to the last detail while delivering a pain-free dental experience.

With hundreds of patients attended to, the team at Aesthetic Dental Center of Morris County remains committed to delivering a 5-star dental care experience that begins when the patient steps foot into the clinic.

The administrative staff is helpful, friendly, and professional in the discharge of their duties. New patients will find the team helpful throughout and after the registration process. The administrative staff will provide all of the help needed by the new patient during the registration process and with the paperwork. The team also offers information on financing plans, dental services offered, and more.

The dental clinic boasts of a relaxing and comfortable waiting area where patients can wait ahead of their dental appointment. Boasting a spacious dental office and consultation room, patients will enjoy the highest level of privacy as they discuss their dental problems with the attending dentist. The dentist at Aesthetic Dental Center of Morris County ensures that patients are provided the personalized service they need towards getting to the root of their dental problems.

By using the latest and most sophisticated dental equipment and tools, patients are guaranteed accurate diagnosis. The Dover Dentist understands the importance of accurate diagnosis as the first step to the proper treatment of dental problems. Patients will be educated on their dental condition and also offered all of the information they need to know regarding the available treatment options.

The dental team at Aesthetic Dental Center of Morris County offers a wide range of dental care and treatment solutions. Procedures offered at the clinic include general dentistry procedures like oral cancer screening, tooth decay services, regular dental cleanings, dental fillings, teeth whitening treatment, and more.

The dental team also offers comprehensive cosmetic dental solutions aimed at improving the quality of the patient’s smile. Some of the cosmetic dental procedures offered include dental implants for patients who have lost one or more teeth, teeth bleaching, porcelain veneers, as well as Invisalign aligners to correct orthodontic problems and for straighter teeth.

Patients in need of oral surgery intervention can also rely on the dental surgeons at Aesthetic Dental Center of Morris County to handle their needs. The team offers wisdom teeth extractions, tooth extractions, and extraction aftercare services.

Visit Aesthetic Dental Center of Morris County at 600 Mt. Pleasant Ave Suite E, Dover, NJ, 07801, or call (973) 361-6200. For more information, send an email to [email protected] or visit their website.

Media Contact
Company Name: Aesthetic Dental Center of Morris County
Contact Person: Vladmir Meskin DDS
Email: Send Email
Phone: (973) 361-6200
Address:600 Mt. Pleasant Ave Suite

Read More
medicine

The role of herbal medicine in diabetes treatment.

Opinions of Saturday, 14 November 2020

Columnist: Cephas Kwaku Debrah

2020-11-14

The writer is a Teaching Assistant at the Department of Herbal Medicine, KNUSTThe writer is a Teaching Assistant at the Department of Herbal Medicine, KNUST

World Diabetes Day was coined by the World Health Organization (WHO) and the International Diabetes Federation (IDF) in 2006. It has since been celebrated every year on November 14th.

Its purpose has been to promote the need to take coordinated and concerted actions to confront diabetes as a critical global health issue.

Diabetes has now become one of the world’s leading non-communicable diseases that affect the body’s ability to make or use insulin.

There are three main types of diabetes – type 1, type 2 and gestational. The body’s blood sugar levels are remarkably constant and rarely outside the range of 3.5?8.0 mmol/L but if an individual record continues fasting blood sugar over 8 mmo1/L or a random value over 11.1 mmo1/L the person is said to be diabetic.

Common symptoms include frequent urination, fatigue, weight loss, slow wound healing, blurry vision and frequent infections. Diabetes if left untreated may lead to nerve, kidney and eye damage, hearing impairment, foot gangrene, miscarriages, stroke and Alzheimer disease among others.

Significant number of Ghanaians are known to suffer from this disorder with the prevalence increasing with age and being higher in urban than in rural areas. Most patients often struggle to make the necessary lifestyle changes to control blood sugar levels, and most current medications have also been known to have some unfavorable adverse effects.

Role of Herbal medicines

Herbal medicines have over the years played an important role in the management of diabetes and its related complications. Clinical studies and various researches have proven the effectiveness of some medicinal plants and herbal formulations in the management of the disease.

Typical among them include: Charantia mormodica – Bitter melon (Asante twi: Nyanya), Ageratum conyzoides- Goat weed (Asante twi: Guakuro), Azadirachta indica -Neem (Asante twi: Dua Gyane), Bridelia micrantha- Bridelia (Asante twi: Opam fufuo), Hymenocardia acida- Heart fruit (Asante twi: Duakokowa), Morinda lucida – Brimstone tree (Asante twi: Bronyadua Konkroma), Moringa oleifera -Drumstick Tree (Ewe: Babatsi) and Tetrapleura tetraptera- Aidan fruit (Asante twi: Prekese).

The anti-hyperglycemic effects that result from treatment with some of these plants is often due to its ability to improve the performance of pancreatic tissue, which is achieved by increasing insulin secretions or reducing the intestinal absorption of glucose.

Research suggests that medicinal plants do not only promote normal blood sugar levels (normoglycaemia) but are also effective for the management of other conditions and complication associated with it.

Medicinal plants like Baphia nitida -African sandalwood (Asante twi: Odwen) and Spathodea campanulata –African tuliptree (Asante twi: Kokoanisuo) are recommended for the management of diabetic wound, Morinda lucida – Brimstone tree (Asante twi: Bronyadua Konkroma) for diabetic retinopathy, Terminalia catapa –Indian almond (Asante twi: Abrofo nkate?) for diabetic nephropathy with amnesia and Theobroma cacao –Cocoa (Asante twi: Kookoo) for diabetic neuropathy.

As we celebrate World Diabetes Day to promote the importance of taking coordinated and concerted actions

Read More
medicine

American College of Lifestyle Medicine Launches Bill of Rights to Raise Awareness of Lifestyle Medicine’s Role in Type 2 Diabetes Informed Consent and Treatment

The Bill of Rights is a companion to ACLM’s recently launched “Reversing Type 2 Diabetes and Insulin Resistance with Lifestyle Medicine” 18-hour, 20-module, evidence-based CME/CE accredited online course for physicians and health professionals. This is the first comprehensive educational curriculum offered to equip physicians and other health professionals to treat and reverse type 2 diabetes and insulin resistance.  In addition, ACLM recently published a position paper, “Type 2 Diabetes Remission and Lifestyle Medicine: A Position Statement from the American College of Lifestyle Medicine.” ACLM will also present a free webinar, “The Reversibility of Type 2 Diabetes with Lifestyle Medicine—Q & A” on Thursday, Nov. 12 at 12 p.m. CST.

ACLM defines Lifestyle Medicine as the use of an evidence-based, whole food, plant-predominant dietary lifestyle, regular physical activity, restorative sleep, stress management, avoidance of risky substances and positive social connection as a primary therapeutic modality for treatment, reversal and prevention of chronic disease. Addressing lifestyle is the first step in type 2 diabetes and other chronic disease treatment and management guidelines, but it has been overlooked due to a lack of physician training in lifestyle, barriers to practice and a lack of consumer understanding. 

“We believe that a patient does not give fully informed consent if this option is not presented to them at the time of diagnosis,” said ACLM Founding President John Kelly, MD, DipABLM, lead faculty for the new course. “COVID-19 has highlighted the vulnerabilities created by type 2 diabetes, amplifying the urgent need to restore health to those impacted by this lifestyle-related chronic disease, as opposed to simply managing it.”

“COVID-19 has exposed the long-standing issue of racial health disparities in America, as people of color have been disproportionally affected by the pandemic,” said ACLM President Cate Collings, MD, DipABLM.  “While the causes of racial health disparities are many, and include the range of social determinants of health, the most devastating impact is from the significantly higher incidence of chronic disease, most notably type 2 diabetes.

“If you are talking about racial health disparities and are not focused on the disparate impact of type 2 diabetes, you are missing the heart of the matter.”

“Truly addressing racial health disparities will only happen when our nation recognizes the role of lifestyle and trains its clinicians accordingly, fully informs patients, removes the barriers to practicing Lifestyle Medicine and rewards physicians and health professionals for restoring health rather than merely managing disease,” said Kelly. “ACLM is actively addressing each of these areas.”

Diabetes has a devastating impact on the quality of life of millions of Americans.  Treatment for diabetes is also a major contributor to the country’s health care spending. According to the Centers for Disease Control and Prevention, 90 percent of the nation’s $3.3 trillion in annual health care expenditure pays for the treatment of chronic health conditions, including type 2 diabetes. In the United States

Read More
dentist

Scotland’s top dentist says patients shouldn’t be forced into private treatment

People in need of dental treatment should not be put in the “invidious position” of being forced to pay for private treatment because of a backlog of NHS appointments due to the coronavirus shutdown, Scotland’s chief dental officer has said.



a man and woman preparing food in a kitchen


© A dentist treating a patient while in PPE.


Tom Ferris, who has come in for criticism from NHS dentists over a lack of communication about why they had to be shut while private dentists could operate safely, said it was not yet “business as usual”. But he said all dentists were now able to “offer the full range of dental care that was offered pre-Covid”, if to a smaller number patients per day.

He also said the appointment backlog created by NHS surgeries not being open for months would be dealt with through the “clinical expertise” of dentists.

READ MORE: Dentists warn poorer patients in Scotland will lose their teeth under Covid-19 restrictions

Speaking on the BBC radio show Call Kaye yesterday, he said dentistry had changed dramatically, with staff now wearing enhanced PPE, ensuring there was enough time between patients to make surgeries infection free, and ventilation improvements in surgeries.

Challenged about the length of time it took for NHS dentists to be able to offer routine treatments while private surgeries were open, he said: “The amount of private dentistry is relatively small. I was trying to plan the reopening of 1,100 dental practices across Scotland.

“Some practices were able to get PPE at an enhanced rate and passed that charge to patients as part of the private fee. I was trying to get every practice access to PPE to allow them to all open at the same time which was a much bigger logistical problem.”

He added: “Private dentists don’t work to different standards, but a private arrangement with a dentist and patient is between the two of them. The NHS system takes in 94 per cent of the Scottish population, and is over 3,000 dentists, so the scale is much bigger.

“We were going safely because had it gone wrong in a private practice and caused a cluster of transmission, it was a very small number of individuals involved. Had it happened systemically across the whole of NHS dentistry, that would have been a much more difficult issue to deal with. We had to be cautious.”

Asked if the problem had been supply of the right PPE to NHS dentists, he added: “We have the PPE, it was the logistics of getting it out to 1,100 different practices which was the issue. The NHS has never provided PPE to practices before March. This is a new way of operating.

“And because the PPE supply was so disrupted in the early months of the pandemic, we were very reliant on Chinese suppliers. We now have Scottish suppliers so the supply chain is much more secure and we have that PPE going out to dental practices.”

Mr Ferris also denied that people were forced to go private for

Read More
health

Oregon Measure 110 on drug recovery treatment: live results

  • Measure 110 in Oregon would provide drug recovery services partially funded through marijuana taxes. 
  • Polls in Oregon closed at 11 p.m. ET.
  • The measure would also reclassify the penalties for specified drugs.
  • Insider will have live results on the propositions as soon as they come in.
  • Visit Business Insider’s homepage for more stories.

Polls in Oregon closed at 11 p.m. ET.

Oregon’s 2020 ballot includes Measure 110, which would provide statewide drug recovery services partially funded by marijuana taxes and would reclassify the penalties for certain drugs.

The text for Oregon Measure 110 reads as follows:

Summary

Measure mandates establishment/ funding of “addiction recovery centers” (centers) within each existing coordinated care organization service area by October 1, 2021; centers provide drug users with triage, health assessments, treatment, recovery services. To fund centers, measure dedicates all marijuana tax revenue above $11,250,000 quarterly, legislative appropriations, and any savings from reductions in arrests, incarceration, supervision resulting from the measure. Reduces marijuana tax revenue for other uses. Measure reclassifies personal non-commercial possession of certain drugs under specified amount from misdemeanor or felony (depending on person’s criminal history) to Class E violation subject to either $100 fine or a completed health assessment by center. Oregon Health Authority establishes council to distribute funds/ oversee implementation of centers. Secretary of State audits biennially. Other provisions.

Result of “Yes” Vote

“Yes” vote provides addiction recovery centers/services; marijuana taxes partially finance (reduces revenues for other purposes); reclassifies possession of specified drugs, reduces penalties; requires audits.

Result of “No” Vote

“No” vote rejects requiring addiction recovery centers/services; retains current marijuana tax revenue uses; maintains current classifications/ penalties for possession of drugs.

Source Article

Read More
health

U.S. Experts to Review Biogen Drug That Could Be First New Alzheimer’s Treatment in Decades | Top News

(Reuters) – U.S. health experts this week will decide whether to recommend approval for Biogen Inc’s

Alzheimer’s drug, which could become the first new treatment for the mind-wasting disease in decades even as serious questions persist over whether data show if it works.

In a field littered with unrelenting failure, Biogen believes in aducanumab it has the first drug that can treat an underlying cause, and therefore slow progression, of Alzheimer’s. But its path to approval has been anything but smooth or assured.

Biogen abruptly ended clinical trials of aducanumab last year after an early look at trial results showed it was not effective. Last October, the company shocked many Alzheimer’s experts by reversing course, saying that a new analysis showed aducanumab could help patients with early-stage disease preserve their ability to function independently for longer. In July, Biogen filed for approval from the Food and Drug Administration.

Now the agency faces tremendous pressure to approve a treatment option for millions of Americans suffering from Alzheimer’s and the millions more expected to face it in coming years.

Patient advocates say the need for a new Alzheimer’s treatment that could help people remain independent is heightened by the coronavirus pandemic, which has killed more than 229,000 people in the United States, including tens of thousands of seniors in nursing homes.

“The pandemic came and it changed everything,” said Russ Paulsen, chief operating officer at patient advocacy group UsAgainstAlzheimer’s. “We need something to keep people out of nursing homes.”

A committee of outside advisers to the FDA will discuss aducanumab on Nov. 6. The agency’s final decision is expected by March. European health regulators have also accepted the drug for review.

Charles Flagg, a 79-year-old retired minister from Jamestown, Rhode Island, had been enrolled for years in a trial of aducanumab before it was stopped. He started receiving the drug again in August as part of a follow-up study, according to his wife Cynthia Flagg.

“He’s not 100 percent himself, but overall I’m not dealing with someone that needs to be led around or be in a care home,” Flagg said.

Aducanumab, an antibody designed to remove amyloid plaques from the brain – a strategy tried with many failed Alzheimer’s drugs – would reap billions of dollars in sales if approved.

Biogen, along with partner Eisai Co Ltd <4523.T>, is one of the last large drugmakers pursuing treatments for a disease that afflicts nearly 6 million Americans and millions more worldwide. Biogen estimates about 1.5 million people with early Alzheimer’s in the United States could be candidates for the drug.

Late last year, Biogen said one of its two pivotal studies of aducanumab showed a statistically significant benefit at slowing cognitive and functional decline in patients with early Alzheimer’s. A second trial failed to achieve that goal, but did show a benefit for a subset of patients who were given a high dose for at least 10 months.

In March, it opened a follow-up long-term safety study to 2,400 people who had

Read More
dentist

Can I go to the dentist in lockdown? Here’s how new restrictions effect treatment

A fresh lockdown coming into force within days will have left many frantically cancelling appointments.

But a date with the dentist is a vital service – and many will be concerned they will lose their appointments as businesses are forced to shut down once again.

Dentists were closed to all but emergency appointments during the early stages of the first lockdown. 

But there will be different rules in place for the second national lockdown, which comes into force from Thursday, October 5, until at least Wednesday, December 2.

People will be allowed to leave their homes for medical appointments

Dentists will remain open during the fresh coronavirus lockdown that kicks in on Thursday, it has been confirmed.

They will remain open for appointments, including regular check-ups during England’s second major shut-down.

Businesses including non-essential shops will be forced to closed once again in the government’s latest bid to curb spread of Covid-19.

But the British Association of Private Dentistry assured dental practices were considered essential.

The association tweeted: “Despite an impending lockdown private practices will remain OPEN.

“It’s safe and essential to attend the dentist.

“We remain open to all, for both routine and emergency treatments. #DentalCare”.

One of the reasons people are permitted to leave their home is for “medical reasons, appointments or to escape injury”.


Boris Johnson urged people to continue to use the NHS for treatment during his speech on Saturday, in which he outlined the new rules.

He said: “So please – this is really important – unless your clinicians tell you otherwise, you should continue to use the NHS, get your scans, turn up for your appointments and pick up your treatments.

“If at all possible, we want you to continue to access these services, now and through the winter.

“Indeed it’s only by taking this action that we can protect the NHS for you.”

Under the new rules, people are allowed to leave the house for a limited number of reasons.

There will be no time limit on how long people can go out for exercise.

People can also go outdoors for recreation with their own household, or on their own with one person from another household.

People will not be allowed to meet in homes and gardens, except for with members of their household ‘bubble’.

People can also leave home to shop for food and essentials and to provide care for vulnerable people or volunteering work.

Overnight stays outside of the home will only be allowed for work purposes, the new rules state.

Click here for a list of reasons you are allowed to leave the house under the new coronavirus lockdown rules.

Read More
health

European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

  • Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved in Europe for the treatment of unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer

  • Tecentriq combination improved overall survival and progression-free survival compared with the previous standard of care

Basel, 2 November 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We’re delighted that people in Europe can now benefit from this combination and we look forward to working with individual countries within the EU to ensure people can access the combination as soon as possible.”

“The results of the IMbrave150 study mark a breakthrough in the treatment of advanced liver cancer, one of the few cancers with a rising death rate and limited options in the first-line setting,” said Dr Arndt Vogel, Professor of Medicine at Hannover Medical School. “After many failures in the last 12 years, the combination of Tecentriq and Avastin shows improvement in overall survival compared to sorafenib and offers patients the opportunity for improved disease control with a high overall response rate.”

The approval is based on results from the Phase III IMbrave150 study, which showed that Tecentriq in combination with Avastin reduced the risk of death (overall survival [OS]) by 42% (hazard ratio [HR]=0.58; 95% CI: 0.42–0.79; p=0.0006) and reduced the risk of disease worsening or death (progression-free survival [PFS]) by 41% (HR=0.59; 95% CI: 0.47–0.76; p<0.0001), compared with sorafenib. IMbrave150 is the first Phase III cancer immunotherapy study to show an improvement in both OS and PFS in people with unresectable HCC compared with sorafenib. Grade 3–4 adverse events occurred in 57% of people receiving Tecentriq and Avastin and 55% of people receiving sorafenib. The most frequent serious adverse reactions for the combination (≥2%) were bleeding in the gastrointestinal tract and fever. These results were published in the New England Journal of Medicine on 14 May 2020.

Today’s approval follows a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in September 2020. In May 2020, the US Food and Drug Administration approved Tecentriq in combination with Avastin for the treatment of people with unresectable or metastatic HCC who have not received prior systemic therapy. In addition, in October 2020 the China National Medical Products Administration approved the combination for the treatment of people with unresectable HCC who have not received prior systemic therapy. In total, the combination is now approved in 59 countries for people with unresectable HCC. Tecentriq in combination with Avastin was also recently included as

Read More
health

Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today

BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, will host a live virtual R&D Day Webinar, with presentations by key opinion leaders in hematology, today from 1:00 – 3:00 pm Eastern Time.

R&D Day Webinar Agenda:

1:00 pm – 2:00 pm:
Introduction and discussion with Drs. David Sallman (Moffitt Cancer Center), Guillermo Garcia-Manero (MD Anderson Cancer Center), and Eyal Attar (Aprea’s Chief Medical Officer) to review current clinical therapy options for TP53 mutant MDS/AML patients and the potential role of eprenetapopt. Discussion with review of Aprea’s Phase 3 Clinical program in MDS to be followed by Q&A.

2:00 pm – 2:15 pm:
Overview of Aprea’s ongoing commercial preparations in front-line MDS by Greg Wessels, Aprea’s Chief Commercial Officer

2:15 pm – 3:00 pm:
Review of Aprea’s hematology and solid tumor clinical pipeline, by Dr. Eyal Attar followed by Q&A and Wrap-up.

Virtual R&D Day Webinar Information

The live webinar will begin at 1:00 pm Eastern Time and conclude at approximately 3:00 pm. Registration is accessible on the Events page of Aprea’s website. Following the webinar, a replay will be available for a limited time on Aprea’s website.

About Aprea Therapeutics

Aprea Therapeutics, Inc., (NASDAQ: APRE) is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein p53. The Company’s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Eprenetapopt has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the European Commission for MDS, AML and ovarian cancer. APR-548, a next-generation small molecule reactivator of mutant p53, is being developed for oral administration. For more information, please visit the company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

About p53, eprenetapopt and APR-548
The p53 tumor suppressor gene is the most frequently mutated gene in human cancer, occurring in approximately 50% of all human tumors. These mutations are often associated with resistance to anti-cancer drugs and poor overall survival, representing a major unmet medical need in the treatment of cancer.

Eprenetapopt is a small molecule that has demonstrated reactivation of mutant and inactivated p53 protein – by restoring wild-type p53 conformation and function – and thereby induce programmed cell death in human cancer cells. Pre-clinical anti-tumor activity has been observed with eprenetapopt in a wide variety of solid and hematological cancers, including MDS, AML, and ovarian cancer, among others. Additionally, strong synergy has been seen with both traditional anti-cancer agents, such as chemotherapy, as well as newer mechanism-based anti-cancer drugs and immuno-oncology checkpoint

Read More